Abstract Details

Title Association of Serum Uric acid with Amyotrophic lateral sclerosis

Topic General Neurology

Presentation(s) S57 - General Neurology: Diagnostic Testing and Disease Biomarkers (3:30 PM-3:42 PM)

Poster/Presentation
Number 001

Objective

To investigate serum UA levels in ALS & to relate them to disease process and disease status.

Background ALS is a progressive degenerative disease of the motor neurons of motor cortex, brainstem, and spinal cord. In contrast to many other disease states, low UA levels are found in many neurodegenerative diseases. It has been suggested that oxidative stress is one of the pathogenic mechanism for ALS, and thus antioxidants such as UA that could reduce oxidative stress might be beneficial in the early detection of progression of the disease.

Design/Methods

ALS patients and healthy controls who were individually well-matched for age, sex, & BMI underwent blood testing for UA levels, and analyzed whether UA levels were correlated with the disease status of the patients, severity of the disease as defined by the ALS Functional Rating Scale-Revised (ALSFRS-R) and duration of illness.

Results The study included 37 ALS patients and 37 matched controls. UA level was lower in the ALS patients (4.29 mg/dl ±1.35 mg/dL, mean±SD) than in the controls (6.26 mg/dL±1.22 mg/dL; p<0.001). Female ALS patients had significantly lower (3.55 mg/dl± 0.89 mg/dL) than Male ALS patients (4.53 mg/dl±1.4 mg/dL; p<0.05). Among the ALS patients, the lower level of UA acid was strongly correlated with the rate of disease progression (decrease in ALSFRS-R score) p<0.001. Uric acid level is inversely correlated with the duration of the disease (r -0.32). Respondents with smoking history group showed more likely to develop ALS than the respondents with no smoking history.

Conclusions

ALS had lower UA than did healthy individuals and it is significantly lower in Female ALS than Male ALS . UA in ALS were positively correlated with the ALSFRS-R (severity) and negatively associated with duration of illness. UA levels could be considered a biomarker of disease progression in the early phase in ALS patients.

Authors/Disclosures
Md Raknuzzaman, MD (National Institute of Neurosciences & Hospital) PRESENTER	No disclosure on file

��ɫ��

��ɫ��